Blog Profile / In the Pipeline

Filed Under:Medical / Pharmaceutical
Posts on Regator:2030
Posts / Week:8.7
Archived Since:November 3, 2010

Blog Post Archive

CRISPR Gene Editing in Human Embryos: Not So Fast

As you'll have heard, the rumors that CRISPR/Cas9 experiments had been performed on human embryonic tissue have turned out to be true. The recent calls for a temporary moratorium on such work were said to have been prompted by word that...Show More Summary

What Are the Odds of Finding a Drug (And How Do You Stand Them?)

Lisa Jarvis of C&E News asked a question on Twitter that's worth some back-of-the-envelope calculation: what are the odds of a medicinal chemist discovering a drug during his or her career? And (I checked) she means "personally synthesizing the compound that makes it to market". Show More Summary

Genervon and ALS: What's Going On Here?

Ever hear of Genervon, and their ALS therapy, GM604? There's not too much to hear about, unless of course you're a desperate patient or relative, looking for something, anything that might help. Genervon is certainly trying to reach those people, with press releases that include phrases such as "dramatic" and "very robust". Show More Summary

The Vibrational Theory of Smell: A Counterattack

I've written here a few times about the vibrational theory of olfaction (and Luca Turin's efforts to revive and prove it). This is an attempt to add a new mode to the existing shape/size/polarity ones known to affect the olfactory receptors - the idea is that some of them may actually sense molecular vibrational modes through electron transfer. Show More Summary

Best And Worst Areas for Drug Discovery

I'm traveling today, with no time to do a full blog post. So I'm going to toss out a couple of questions for everyone: What diseases or therapeutic areas do you think have the best opportunities now for "traditional" small-molecule drug...Show More Summary

PD-1 Charted

Via AndyBiotech on Twitter, here's a chart from the ongoing AACR meeting on what sorts of tumors are responding best to the PD-1 antibodies that are creating such excitement. You can look at this two ways - what parts of oncology practice are on their way to being transformed, and/or what parts still have a big need for small molecules (!) Here's more from Matthew Herper.

Dr. Oz Under Fire

You'll have heard that a group of physicians has written a public letter to Columbia University asking why Dr. Oz is still on the faculty there. Here's the text, and it includes some heartwarming stuff: ...We are surprised and dismayed that Columbia University's College of Physicians and Surgeons would permit Dr. Show More Summary

Stopped For Efficacy - Again

Well, just weeks after Merck halted a trial of their anti PD-1 antibody Keytruda (pembrolizumab) due to efficacy, Bristol-Myers Squibb has announced that a trial of their own PD-1 antibody, Opdivo (nivolumab) against non-squamous non-small-cell lung cancer has been halted for the same reason: it's working so well that it's unethical to continue. Show More Summary

You Have One Minute

The European Federation for Medicinal Chemistry has a competition open, for the best one-minute video explaining what medicinal chemistry is and why it's important. Here's the link - the prize is 500 euros, and fame/fortune/etc. "Why...Show More Summary

That Can't Be Right

Crazy structure alert! See Arr Oh has pointed out a paper that appeared a few months ago in PLoS ONE, describing a new antibiotic. Yep, that's it at left. Note that it's a symmetric sulfoxide, with those...unusual groups on each side. Show More Summary

How Many Chemists Have You Seen on a Team?

I'm traveling today to give a talk (at this regional meeting of the AAPS), so I don't have my usual train commute wherein to do the morning blog post. So I wanted to set off a bit of discussion instead. I had an email from someone whose...Show More Summary

Using the Same FEP Ruler

With free energy perturbation having its time in the calculational spotlight, thanks to Schrödinger and others, it seems worthwhile to link to this new paper. It's a proposal for a common framework to analyze the results of such work. Show More Summary

Dealing With Cranks

Here's a good article at Vox about what to do with idiots like the Food Babe and Dr. Oz. (OK, perhaps he just plays an idiot on TV, but by this point you have to wonder). Like any scientist with any sort of public platform, I've wondered about this, too. Show More Summary

Finding Placebo Responders

We all know about the placebo effect - in some therapeutic areas (depression being a classic case), it's so strong that finding a drug that works better is no small feat. And it's been thought for some time that the strength of the placebo response varies from patient to patient, in ways that aren't really understood. Show More Summary

Big Monofluorination Review

Here's a comprehensive and very timely review on monofluorination methods. 84 pages, before you get to the references, and there are 562 of those! It covers the last ten years of the literature, a busy time indeed in the organofluorine field, and no one should be without it who's interested in fluorination. That means pretty much all medicinal chemists - enjoy!

Blog Post Title Goes Here

A colleague tells me that he just got a come-on from yet another unknown open-source journal, "Pharmaceutical Chemistry Review". Reproduced below, word-for-word, is the pitch. And it's hard to resist when they butter you up like this: Dear...Show More Summary

Looking Back At Merck/Schering-Plough

Here's Ed Silverman at Pharmalot, looking back at the Merck/Schering-Plough merger. It has not gone quite like the initial plan: First, a little history. In November 2008, Schering-Plough Chief Executive Fred Hassan told analysts and...Show More Summary

Better Drinking Through Chemistry

This is a fascinating article about a guy who's looking into the chemistry of aged spirits - rum, whiskey, cognac, and so on - and trying to find ways, as he puts it, to hack the process. I'm not a drinker myself, but I've watched with interest as the craft spirits movement has become popular. Show More Summary

Hollow Fiber Flow

Flow chemistry has a lot of potential for catalyzed reactions - just keep flowing your starting materials across the catalyst, and product comes hosing out the other end. Well, in theory. In practice, although this sort of thing is done on gigantic scale in the chemical industry, it can take a fair amount of engineering. Show More Summary

Teaching Chemistry, According to the Press

You know how most newspaper articles that deal with chemistry show that the writer didn't know very much about chemistry? Well, it looks as if people know even less about how chemistry is actually taught. Chemjobber has more here. I'll echo his question: do they really not teach anyone at Emory what a bond is until sophomore year? Or did someone garble that part, too

Copyright © 2015 Regator, LLC